Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

161 / 244

Methods: Thirty-one Japanese patients hospitalized to our
hospital with diabetes for education were recruited. BMD of
various parts and body composition were measured by DXA
and fat mass index [FMI (kg/m 2)], lean mass index [LMI (kg/
m2)], and Z-scores of the lumbar spine (L-Z), the femoral
neck (FN-Z), and the radius (R-Z) were evaluated. Z-scores
were calculated on the basis of normal reference values of
the age- and sex-matched Japanese group. Simple regression
analysis using L-Z, FN-Z and R-Z as dependent variables
and years from diagnosis, body weight, BMI, FMI, LMI, urine
albumin (U-A), HbA1c, serum C-peptide, eGFR, bone turnover
markers (serum ucOC, BAP, and TRACP-5b, and urine NTX),
systolic blood pressure (SBP), ankle brachial index (ABI),
cardio ankle vascular index (CAVI) and HDL-C as independent
variables were performed. Stepwise multiple regression
analysis using L-Z, FN-Z and R-Z as dependent variables
and years from diagnosis, U-A, HbA1c, CPR, eGFR, BAP,
TRACP-5b, SBP, FMI, LMI and CAVI as independent variables
were performed.
Results: [clinical background (mean ± SD)] Number of subjects:
31 (21 males, 10 females; type 1: 2, type 2: 28, other: 1);
therapeutic method: diet only 1, oral hypoglycemic agents
(OHA) without insulin 19 (one patient used pioglitazone at
admission), insulin 11; age: 57.3 ± 14.3; BMI: 26.4 ± 5.7; Years
from diagnosis: 7.3 ± 6.1 [simple regression analysis] L-Z was
correlated with FMI (R = 0.463) and HDL-C (R = −0.444). FN-Z
was correlated with FMI (R = 0.413) and HDL-C (R = −0.368). R-Z
was correlatedwith BMI (R = 0.458) and FMI (R = 0.590). No other
factors were correlated with Z-sores; interestingly, body
weight and LMI were not correlated with Z-scores. [stepwise
multiple regression analysis] L-Z, FN-Z and R-Z were inde-
pendently predicted by FMI, accounting for 21.0%, 12.0%
and 27.7% of the variability of the dependent variables,
respectively.
Conclusion: Indices of bone turnover, glycemic control, renal
function, endogenous insulin secretion, nephropathy, athero-
sclerosis, and other clinical factors were not correlated with
BMD in this small study. A positive correlation between bone
mineral density and fat mass was found in these Japanese
patients with diabetes.
PE-39
Cilostazol effectively attenuates deterioration of albuminuria
in patients with type 2 diabetes: a randomized, placebo-
controlled trial
Wen-Hao TANG 1, Fu-Huang LIN1, Chien-Hsing LEE1*,
Feng-Chih KUO 1, Chang-Hsun HSIEH1, Fone-Ching HSIAO1,
Yi-Jen HUNG 1. 1Division of Endocrinology and Metabolism,
Department of Internal Medicine, Tri-Service General Hospital,
National Defense Medical Center, Nei-Hu, Taiwan
Cilostazol is an antiplatelet, antithrombotic agent with anti-
inflammatory properties. To date, no clinical study has
specifically evaluated the efficacy of cilostazol in patients
with diabetic nephropathy (DN). We hypothesized that cilos-
tazol might delay renal deterioration in DN patients at high
risk of progression. Between April 2008 and April 2010, we
screened 156 consecutive patients aged 35–80 years who were
first diagnosed with type 2 diabetes after the age of 30 years. Of
these, 90 patients with DN, as defined by morning spot urine
microalbuminuria (MAU) [20 mg/L or an albumin-to-creatinine
ratio (ACR)[30 lg/mg on at least two consecutive occasions
within the prior 3 months, were enrolled into a 52-week
randomized, single-blinded, placebo-controlled trial of oral
cilostazol 100 mg twice daily or placebo (45 subjects in each
group). Morning spot urine samples were collected to
determineMAUand ACR. Fasting plasma levels of metabolic,
endothelial variables, and inflammatory markers were exam-
ined. Following 52 weeks of treatment, urinary MAU and ACR
were significantly reduced in the cilostazol group compared
with the placebo group (P = 0.024 and P = 0.02, respectively).
In regression analyses, changes in monocyte chemotactic
protein-1, E-selectin, and soluble vascular cell adhesion
molecule-1 (sVCAM-1) were significantly associated with
changes in MAU and ACR. Net changes of E-selectin (P\0.001)
and sVCAM-1 (P\0.05) were independent predictors of change
in MAU and ACR, respectively. Our results suggest that
cilostazol may effectively attenuate deterioration of albumin-
uria in patients with type 2 diabetes. This effect is likely
mediated by an improvement of adhesion molecules.
PE-40
Relationship between serum iron with renal function of
subjects with diabetes
Xiaojuan SHAO1*, Wen HU1, Weinan YU 1. 1Huai’an Hospital
Affiliated to Xuzhou Medical School, China
Objective: To explore the value of serum iron in the diagnosis
of type 2 diabetes mellitus (T2DM) with the decline of renal
function.
Methods: A total of 100 subjects who were diagnosed T2DM
were recruited from the second people’s hospital of Huai ‘an
from February to March in 2016. We collected the baseline data
and measure serum iron, renal artery doppler ultrasound and
GFR determination of nuclide renal dynamic imaging.
Results: Serum iron levels were negatively correlated with
nuclide GFR (r = 0.214, P < 0.05).
Conclusion: Serum iron is an independent risk factor for the
decline of kidney function in patients with T2DM.
PE-41
Potential nephroprotective effects of type 2 diabetes therapy:
Epidemiologic study for South East Asian and Arab
populations in Qatar
Kerry WILBUR1*, Ahmed MITHA2, Nadya ADULMULLA2. 1Qatar
University College of Pharmacy, 2Qatar Petroleum, Qatar
Purpose: Metformin is considered a first line therapy for
patients with type 2 diabetes mellitus (T2DM). Increasingly
evidence is emerging to support not only the safe use of
metformin in patients with impaired renal function, but
epidemiologic study among Caucasian populations have
demonstrated a potential nephroprotective effect. The object-
ive of this study is to evaluate the relationship between
metformin and renal outcomes in South East Asian and Arab
patients with T2DM in Qatar.
Methods: A retrospective cohort study of patients with T2DM
enrolled in health care services provided by Qatar Petroleum,
the largest private employer in Doha, Qatar, is being con-
ducted. Patients who received care between 1995 and 2015 are
considered. Any adult who received an incident oral glucose
lowering drug prescription during the study period will be
considered for inclusion (“new user”). Incident prescriptions
will be defined as the first oral glucose lowering drug
prescription filled after at least 365 days of active use of QP
medical services without prescriptions filled for any other oral
glucose lowering drug (“baseline year”). Patient health datawill
be followed from “index date” (date of incident prescription)
until documented development of a study outcome or a
censoring event, such as: leaving the QP medical system;
non-persistence on the incident oral glucose lowering drug;
switching or adding new oral glucose lowering drug to the
original therapy. Exposure categories will be grouped accord-
ing to different glucose lowering regimens cohorts. The
primary outcome will be a composite of: a GFR event, defined
as a persistent 25% or greater decline from the baseline eGFR;
reaching ESRD, defined as reaching one of the following: an
eGFR < 15 mL/min/1.73 m2 or documented initiation of dialysis
or kidney transplant. GFR and ESRD events will be confirmed
between 3 and 12 months after the first documented outcome
in order to avoid counting episodes of reversible acute kidney
injury.
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S143